Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Share-based Compensation (2022 - 2025)

Stoke Therapeutics has reported Share-based Compensation over the past 4 years, most recently at $9.8 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $9.8 million for Q4 2025, up 37.95% from a year ago — trailing twelve months through Dec 2025 was $32.2 million (up 17.36% YoY), and the annual figure for FY2025 was $32.2 million, up 17.36%.
  • Share-based Compensation for Q4 2025 was $9.8 million at Stoke Therapeutics, up from $8.0 million in the prior quarter.
  • Over the last five years, Share-based Compensation for STOK hit a ceiling of $9.8 million in Q4 2025 and a floor of $5.0 million in Q1 2022.
  • Median Share-based Compensation over the past 4 years was $6.7 million (2023), compared with a mean of $6.7 million.
  • Biggest five-year swings in Share-based Compensation: fell 8.1% in 2024 and later soared 37.95% in 2025.
  • Stoke Therapeutics' Share-based Compensation stood at $5.8 million in 2022, then rose by 3.8% to $6.1 million in 2023, then rose by 17.84% to $7.1 million in 2024, then soared by 37.95% to $9.8 million in 2025.
  • The last three reported values for Share-based Compensation were $9.8 million (Q4 2025), $8.0 million (Q3 2025), and $7.6 million (Q2 2025) per Business Quant data.